Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TP53BP1 | Q12888 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19750417 | 0.98 | KDM4E (0.70) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL18346903 | 0.98 | KDM4E (0.70) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL14043307 | 0.95 | KDM4E (0.58) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL7751127 | 0.86 | KDM4E (0.50) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL860791 | 0.83 | KDM4E (0.94) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL23790074 | 0.82 | KDM4E (0.59) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL5791843 | 0.82 | POLB (0.44) | KDM4EMAPK1HIF1AADRA1ATP53BP1 | |
| SCHEMBL5794590 | 0.80 | KDM4E (0.44) | KDM4EMAPK1HIF1AADRA1ATP53BP1 | |
| SCHEMBL23594056 | 0.80 | POLB (0.49) | KDM4EMAPK1HIF1ATP53BP1ALDH1A1 | |
| SCHEMBL27977111 | 0.80 | KDM4E (0.44) | KDM4EMAPK1HIF1AADRA1ATP53BP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-11685722-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11242323-B2 | Inhibition of OLIG2 activity | Curtana Pharmaceuticals, Inc. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-04 | — | — | US | disclosed |
| US-20210253535-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2021-08-19 | — | — | US | disclosed |
| US-11008302-B2 | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-18 | — | — | US | disclosed |
| US-20200407329-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2020-12-31 | — | — | US | disclosed |
| US-20190308950-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308950-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3B | KDM4E 2973/4885MAPK1 1550/4885HIF1A 2756/4885 |
| US-20210253535-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | KDM4E 2547/4885MAPK1 2001/4885HIF1A 839/4885 |
| US-11685722-B2 | Inhibition of Olig2 activity | GLI2, ING2, GMFG | KDM4E 2547/4885MAPK1 2001/4885HIF1A 839/4885 |
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3B | KDM4E 2973/4885MAPK1 1550/4885HIF1A 2756/4885 |
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, CBL, XIAP | KDM4E 1076/4885MAPK1 2171/4885HIF1A 3905/4885 |
| US-11242323-B2 | Inhibition of OLIG2 activity | POU2F2, ING2, PAX2 | KDM4E 2188/4885MAPK1 2474/4885HIF1A 664/4885 |
| US-20200407329-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | KDM4E 2547/4885MAPK1 2001/4885HIF1A 839/4885 |
| US-11008302-B2 | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators | GRIN2B, GRIN2A, GRIN3B | KDM4E 3194/4885MAPK1 1345/4885HIF1A 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.